TY  - JOUR
AU  - Lorscheider, J
AU  - Kuhle, J
AU  - Izquierdo, G
AU  - Lugaresi, A
AU  - Havrdova, E
AU  - Horakova, D
AU  - Hupperts, R
AU  - Duquette, P
AU  - Girard, M
AU  - Prat, A
AU  - Grand'Maison, F
AU  - Grammond, P
AU  - Sola, P
AU  - Ferraro, D
AU  - Trojano, M
AU  - Ramo-Tello, C
AU  - Lechner-Scott, J
AU  - Pucci, E
AU  - Solaro, C
AU  - Slee, M
AU  - Van Pesch, V
AU  - Sanchez Menoyo, J L
AU  - van der Walt, A
AU  - Butzkueven, H
AU  - Kappos, L
AU  - Kalincik, T
AU  - MSBase Study Group
PY  - 2018
DO  - 10.1111/ene.13824
UR  - http://hdl.handle.net/10668/13050
T2  - European journal of neurology
AB  - Treatment options in primary progressive multiple sclerosis (PPMS) are scarce and, with the exception of ocrelizumab, anti-inflammatory agents have failed to show efficacy in ameliorating disability progression. The aim of this study was to...
LA  - en
KW  - clinical outcomes
KW  - immunomodulation
KW  - multiple sclerosis
KW  - observational study
KW  - primary progressive
KW  - Adult
KW  - Anti-Inflammatory Agents
KW  - Antibodies, Monoclonal, Humanized
KW  - Cohort Studies
KW  - Disability Evaluation
KW  - Disabled Persons
KW  - Disease Progression
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis, Chronic Progressive
TI  - Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
TY  - research article
VL  - 26
ER  -